Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467690 | 0.89 | IDO1 (0.47) | IDO1PDPK1 | |
| SCHEMBL829496 | 0.88 | HTR6 (0.43) | HTR6IDO1 | |
| Ethoxycarbonyl Group SCHEMBL28770651 | 0.87 | HTR6 (0.40) | HTR6MTNR1AMTNR1BIDO1PDPK1 | |
| SCHEMBL2325962 | 0.82 | MTNR1A (0.50) | HTR6MTNR1AMTNR1BIDO1PDPK1 | |
| SCHEMBL3100368 | 0.81 | HTR1A (0.55) | HTR6MTNR1AMTNR1BIDO1PDPK1 | |
| SCHEMBL31355113 | 0.80 | HTR6 (0.49) | HTR6MTNR1AMTNR1BIDO1PDPK1 | |
| SCHEMBL31355114 | 0.80 | HTR6 (0.49) | HTR6MTNR1AMTNR1BIDO1PDPK1 | |
| SCHEMBL7683388 | 0.80 | MTNR1A (0.48) | HTR6MTNR1AMTNR1B | |
| SCHEMBL1568298 | 0.79 | HTR6 (0.54) | HTR6MTNR1AMTNR1BIDO1PDPK1 | |
| Hydrochloric Acid SCHEMBL27504897 | 0.79 | HTR6 (0.54) | HTR6MTNR1AMTNR1BIDO1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260080976-A1 | SYSTEM AND METHODS FOR GENERATION OF FRAGMENT MODULE LIBRARIES FOR LEAD OPTIMIZATION OF PHARMACEUTICALLY ACTIVE MOLECULES | PURDUE RESEARCH FOUNDATION (US) | 2026-03-19 | — | — | US | disclosed |
| US-8143304-B2 | (3-amino-1,2,3,4-tetrahydro-9 H-carbazol-9-yl)-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2051962-B1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20110251393-A1 | HELICENE DERIVATIVE, AXIALLY ASYMMETRIC AMINO ACID, AMINE OR AMINOALCOHOL DERIVATIVE, PERYLENE DERIVATIVE OR SALT THEREOF, AND METHODS FOR PRODUCING SAME | KYOTO UNIVERSITY (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2357177-A1 | HELICENE DERIVATIVE, AXIALLY ASYMMETRIC AMINO ACID, AMINE OR AMINOALCOHOL DERIVATIVE, PERYLENE DERIVATIVE OR SALT THEREOF, AND METHODS FOR PRODUCING SAME | Kyoto University (JP) | 2011-08-17 | — | — | EP | disclosed |
| EP-2316824-A1 | (3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates | Actelion Pharmaceuticals Ltd. (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-29 | — | — | US | disclosed |
| CN-100543022-C | 2-furancarboxylic acid hydrazide compound and contain the pharmaceutical composition of this compound | DAINIPPON PHARMACEUTICAL CO (JP) | 2009-09-23 | — | — | CN | disclosed |
| EP-2051962-A1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-08-28 | — | — | US | disclosed |
| WO-2008095058-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008017989-A1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-14 | — | — | WO | disclosed |
| EP-1761618-A1 | USE OF A MIXTURE OF CIS- AND TRANS-3-METHYL-G-DECALACTONE AND COMPOSITIONS OF ODORIFEROUS SUBSTANCES AND PERFUMED ARTICLES COMPRISING SAID MIXTURE | Symrise GmbH & Co. KG (DE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123889-A1 | USE OF A MIXTURE OF CIS- AND TRANS-3-METHYL-G-DECALACTONE AND COMPOSITIONS OF ODORIFEROUS SUBSTANCES AND PERFUMED ARTICLES COMPRISING SAID MIXTURE | SYMRISE GMBH & CO. KG (DE) | 2005-12-29 | — | — | WO | disclosed |
| CN-1628111-A | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-06-15 | — | — | CN | disclosed |
| EP-0661273-B1 | Indane derivatives and processes for preparing the same | TANABE SEIYAKU CO (JP) | 1999-05-19 | — | — | EP | disclosed |
| US-5686452-A | PROTECTING FROM ENDOTOXIN SHOCK; TREATMENT OF NEPHRITIS | TANABE SEIYAKU CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0661273-A1 | Indane derivative and processes for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251393-A1 | HELICENE DERIVATIVE, AXIALLY ASYMMETRIC AMINO ACID, AMINE OR AMINOALCOHOL DERIVATIVE, PERYLENE DERIVATIVE OR SALT THEREOF, AND METHODS FOR PRODUCING SAME | AADAT, AASDHPPT, AZI2 | HTR6 1268/4885MTNR1A 2924/4885MTNR1B 3497/4885 |
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | GLS2, SLC10A1, UGT1A1 | HTR6 2644/4885MTNR1A 796/4885MTNR1B 426/4885 |
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | PTGDR, PTGER1, PTGIR | HTR6 219/4885MTNR1A 148/4885MTNR1B 116/4885 |
| US-20260080976-A1 | SYSTEM AND METHODS FOR GENERATION OF FRAGMENT MODULE LIBRARIES FOR LEAD OPTIMIZATION OF PHARMACEUTICALLY ACTIVE MOLECULES | BACE2, ADAM33, SET | HTR6 246/4885MTNR1A 2407/4885MTNR1B 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.